[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JOP20210109A1 - مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك - Google Patents

مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك

Info

Publication number
JOP20210109A1
JOP20210109A1 JOP/2021/0109A JOP20210109A JOP20210109A1 JO P20210109 A1 JOP20210109 A1 JO P20210109A1 JO P20210109 A JOP20210109 A JO P20210109A JO P20210109 A1 JOP20210109 A1 JO P20210109A1
Authority
JO
Jordan
Prior art keywords
dengue viral
mono
compounds
substituted indole
viral replication
Prior art date
Application number
JOP/2021/0109A
Other languages
English (en)
Inventor
Bart Rudolf Romanie Kesteleyn
Jean-François Bonfanti
Tim Hugo Maria Jonckers
Pierre Jean-Marie Bernard Raboisson
Dorothée Alice Marie-Eve Bardiot
Arnaud Didier M Marchand
Original Assignee
Janssen Pharmaceuticals Inc
Katholieke Univ Leuven Ku Leuven Research And Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Katholieke Univ Leuven Ku Leuven Research And Development filed Critical Janssen Pharmaceuticals Inc
Publication of JOP20210109A1 publication Critical patent/JOP20210109A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات اندول مستبدلة احاديا أو ثنائيا وبطرق لمنع او معالجة الاصابات الفيروسية باستخدام المركبات المذكورة. وكما يتعلق بالمركبات المذكورة بخصوص استخدامها كدواء والافضل لاستخدامها كعلاج لمنع أو معالجة الاصابات الفيروسية لحمى الفنك. كما يتعلق الاختراع الحالي بتركيبات صيدلانية أو مستحضرات متحدة من المركبات، وبالتركيبات أو المستحضرات لاستخدامها كدواء، والافضل لمنع أو معالجة الاصابات الفيروسية لحمى الفنك. كما يتعلق الاخراع بعمليات و طرق لتحضير هذه المركبات
JOP/2021/0109A 2015-05-08 2021-05-10 مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك JOP20210109A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15166900 2015-05-08
EP16163342 2016-03-31

Publications (1)

Publication Number Publication Date
JOP20210109A1 true JOP20210109A1 (ar) 2023-01-30

Family

ID=56026812

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2016/0086A JOP20160086B1 (ar) 2015-05-08 2016-05-03 مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP/2021/0109A JOP20210109A1 (ar) 2015-05-08 2021-05-10 مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JOP/2016/0086A JOP20160086B1 (ar) 2015-05-08 2016-05-03 مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك

Country Status (38)

Country Link
US (4) US10696632B2 (ar)
EP (2) EP3896072B1 (ar)
JP (4) JP6752821B2 (ar)
KR (2) KR102610491B1 (ar)
CN (3) CN113045476B (ar)
AU (2) AU2016259677B2 (ar)
BR (1) BR112017023904A2 (ar)
CA (1) CA2981845C (ar)
CL (1) CL2017002817A1 (ar)
CO (1) CO2017012381A2 (ar)
CR (2) CR20170490A (ar)
CY (1) CY1124548T1 (ar)
DK (1) DK3294738T3 (ar)
EA (1) EA034978B1 (ar)
EC (2) ECSP17073878A (ar)
ES (2) ES2941674T3 (ar)
GT (1) GT201700234A (ar)
HK (2) HK1252446A1 (ar)
HR (1) HRP20210675T1 (ar)
HU (1) HUE054724T2 (ar)
IL (2) IL255430B (ar)
JO (2) JOP20160086B1 (ar)
LT (1) LT3294738T (ar)
MD (1) MD3294738T2 (ar)
MX (2) MX2020011156A (ar)
NI (1) NI201700137A (ar)
PE (2) PE20221579A1 (ar)
PH (1) PH12017502000B1 (ar)
PL (1) PL3294738T3 (ar)
RS (1) RS62029B1 (ar)
SG (1) SG10201900315SA (ar)
SI (1) SI3294738T1 (ar)
SV (1) SV2017005557A (ar)
TW (2) TWI744963B (ar)
UA (2) UA121332C2 (ar)
UY (2) UY39706A (ar)
WO (1) WO2016180696A1 (ar)
ZA (2) ZA201707524B (ar)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN108884033B (zh) 2016-03-31 2021-03-09 杨森制药公司 作为登革病毒复制抑制剂的经取代的吲哚衍生物
WO2017167953A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MA44502A (fr) 2016-04-01 2019-02-06 Janssen Pharmaceuticals Inc Dérivés d'indole substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AU2018274100B2 (en) 2017-05-22 2022-06-23 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
US11053196B2 (en) 2017-05-22 2021-07-06 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
BR112022009199A2 (pt) 2019-11-15 2022-07-26 Janssen Pharmaceuticals Inc Tratamento e prevenção da dengue
WO2022094817A1 (en) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Pharmaceutical formulation
WO2022094816A1 (en) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Solid formulation
CN113024440B (zh) * 2021-03-17 2023-05-16 凯莱英医药集团（天津）股份有限公司 连续化合成取代吲哚-2-羧酸的方法
BR112023027328A2 (pt) 2021-06-29 2024-03-12 Janssen Pharmaceuticals Inc Processos para a preparação de derivados de (s)-2-(4-cloro-2-metoxifenil)-2-((3-metóxi-5-(metilsulfonil)fenil)amino)-1-(1h-indol-3-il)etenona
WO2023218285A1 (en) 2022-05-12 2023-11-16 Janssen Pharmaceuticals, Inc. Treatment or prevention of dengue viral infection
CN115521307B (zh) * 2022-09-30 2023-09-22 甘肃皓天医药科技有限责任公司 一种5-卤代-7-氮杂吲哚的制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021559A1 (en) 1997-10-27 1999-05-06 Eli Lilly And Company MORPHOLINO-N-ETHYL ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
JP2005520795A (ja) 2001-12-12 2005-07-14 コンフォーマ・セラピューティクス・コーポレイション Ｈｓｐ９０阻害活性を有するプリン類似体
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
KR20070098914A (ko) 2005-01-14 2007-10-05 제네랩스 테크놀로지스, 인코포레이티드 바이러스 감염을 치료하기 위한 인돌 유도체
JP2008530124A (ja) 2005-02-09 2008-08-07 ミジェニックス インコーポレイテッド フラビウイルス感染症を処置または予防するための組成物および方法
FR2928645A1 (fr) * 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
BRPI0909985A2 (pt) 2008-06-03 2015-08-25 Siga Technologies Inc Composição farmacêutica e método para o tratamento ou profilaxia de uma infecção viral ou doença associada à mesma
EP2326631A4 (en) * 2008-08-18 2012-03-21 Univ Yale MODULATORS OF MIF
US8143259B2 (en) 2008-08-19 2012-03-27 Janssen Pharmaceutica, Nv Cold menthol receptor antagonists
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
WO2010091413A1 (en) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
EA201290575A1 (ru) 2010-01-15 2013-01-30 Джилид Сайэнс, Инк. Ингибиторы вирусов flaviviridae
US20130023532A1 (en) 2010-03-26 2013-01-24 Casillas Linda N Indazolyl-pyrimidines as kinase inhibitors
JP5716205B2 (ja) 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
US9567299B2 (en) 2013-10-23 2017-02-14 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US20170002006A1 (en) 2014-01-31 2017-01-05 Bristol-Myers Squibb Company Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
PL3926051T3 (pl) 2014-06-04 2024-08-26 Amgen Inc. Sposoby zbierania hodowli komórek ssaczych
US10208286B2 (en) 2014-06-04 2019-02-19 Fred Hutchinson Cancer Research Center Expansion and engraftment of stem cells using Notch 1 and/or Notch 2 agonists
NO2721243T3 (ar) 2014-10-01 2018-10-20
KR102478309B1 (ko) 2014-10-01 2022-12-15 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 １치환 또는 ２치환 인돌
PL3201176T3 (pl) * 2014-10-01 2019-06-28 Janssen Pharmaceuticals, Inc. Mono- lub di-podstawione pochodne indolowe jako inhibitory replikacji wirusa dengi
EP3204517B1 (en) 2014-10-10 2021-08-11 Rutgers, the State University of New Jersey Polymerase chain reaction primers and probes for mycobacterium tuberculosis
JOP20150335B1 (ar) * 2015-01-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3313816B1 (en) 2015-07-22 2023-05-24 OMEICOS Therapeutics GmbH Metabolically robust analogs of cyp-eicosanoids for the treatment of cardiac disease
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AU2016350868B2 (en) 2015-11-03 2022-03-31 Zoetis Services Llc Sol-gel polymer composites and uses thereof
WO2017167953A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
US10323026B2 (en) 2016-03-31 2019-06-18 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN108884033B (zh) 2016-03-31 2021-03-09 杨森制药公司 作为登革病毒复制抑制剂的经取代的吲哚衍生物
EP3436079B1 (en) 2016-04-01 2021-08-25 Kite Pharma, Inc. Chimeric antigen and t cell receptors and methods of use
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
TN2018000337A1 (en) 2016-04-01 2020-01-16 Amgen Inc Chimeric receptors to flt3 and methods of use thereof
SI3436030T1 (sl) 2016-04-01 2023-01-31 Kite Pharma, Inc. Himerni receptorji in načini njihove uporabe
CA3015934A1 (en) 2016-04-01 2017-10-05 Basf Se Bicyclic compounds
SG11201808388QA (en) 2016-04-01 2018-10-30 Signal Pharm Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
MA44502A (fr) 2016-04-01 2019-02-06 Janssen Pharmaceuticals Inc Dérivés d'indole substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
US11053196B2 (en) 2017-05-22 2021-07-06 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
AU2018274100B2 (en) 2017-05-22 2022-06-23 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors

Also Published As

Publication number Publication date
PL3294738T3 (pl) 2021-12-13
GT201700234A (es) 2018-11-26
JP2020125316A (ja) 2020-08-20
EP3896072A1 (en) 2021-10-20
CY1124548T1 (el) 2022-07-22
EP3294738B1 (en) 2021-04-07
SV2017005557A (es) 2018-06-26
KR102610491B1 (ko) 2023-12-06
IL255430A0 (en) 2017-12-31
JP6752821B2 (ja) 2020-09-09
PH12017502000A1 (en) 2018-03-26
HK1252446A1 (zh) 2019-05-24
IL272814B (en) 2021-02-28
CN111303000A (zh) 2020-06-19
IL255430B (en) 2020-03-31
PE20180232A1 (es) 2018-01-31
ECSP17073878A (es) 2018-02-28
AU2020273314A1 (en) 2020-12-17
US11827602B2 (en) 2023-11-28
WO2016180696A1 (en) 2016-11-17
ECSP22023220A (es) 2022-05-31
UY36674A (es) 2016-11-30
US20240182414A1 (en) 2024-06-06
TWI744963B (zh) 2021-11-01
CA2981845C (en) 2022-03-08
PH12017502000B1 (en) 2018-03-26
CN113045476A (zh) 2021-06-29
UA128183C2 (uk) 2024-05-01
ES2877404T3 (es) 2021-11-16
KR20180002644A (ko) 2018-01-08
CL2017002817A1 (es) 2018-05-11
TWI725969B (zh) 2021-05-01
PE20221579A1 (es) 2022-10-06
HUE054724T2 (hu) 2021-09-28
JOP20160086B1 (ar) 2021-08-17
AU2020273314B2 (en) 2021-10-21
ES2941674T3 (es) 2023-05-24
US20210171462A1 (en) 2021-06-10
JP7451626B2 (ja) 2024-03-18
ZA201707524B (en) 2024-06-26
MD3294738T2 (ro) 2021-08-31
JP2022166289A (ja) 2022-11-01
MX2020011156A (es) 2022-04-21
TW202041499A (zh) 2020-11-16
KR20210048578A (ko) 2021-05-03
EA201792429A1 (ru) 2018-02-28
JP2021138752A (ja) 2021-09-16
UY39706A (es) 2022-05-31
US10919854B2 (en) 2021-02-16
EP3294738A1 (en) 2018-03-21
JP7132399B2 (ja) 2022-09-06
JP2018515495A (ja) 2018-06-14
DK3294738T3 (da) 2021-06-28
US20180346419A1 (en) 2018-12-06
HK1252496A1 (zh) 2019-05-31
US20200270209A1 (en) 2020-08-27
CA2981845A1 (en) 2016-11-17
CN107873022B (zh) 2021-03-12
EA034978B1 (ru) 2020-04-14
TW201704208A (zh) 2017-02-01
CN111303000B (zh) 2023-11-28
RS62029B1 (sr) 2021-07-30
US10696632B2 (en) 2020-06-30
SI3294738T1 (sl) 2021-08-31
NZ736934A (en) 2023-11-24
EP3896072B1 (en) 2022-11-16
BR112017023904A2 (pt) 2018-07-17
CO2017012381A2 (es) 2018-03-28
IL272814A (en) 2020-04-30
CR20200152A (es) 2020-09-08
UA121332C2 (uk) 2020-05-12
KR102610493B1 (ko) 2023-12-05
ZA202002435B (en) 2023-03-29
AU2016259677A1 (en) 2017-10-26
LT3294738T (lt) 2021-08-25
AU2016259677B2 (en) 2020-10-01
CN107873022A (zh) 2018-04-03
SG10201900315SA (en) 2019-02-27
MX2017014293A (es) 2018-08-09
NI201700137A (es) 2019-05-07
HRP20210675T1 (hr) 2021-06-25
JP6898493B2 (ja) 2021-07-07
CR20170490A (es) 2018-03-08
CN113045476B (zh) 2024-07-16

Similar Documents

Publication Publication Date Title
JOP20210109A1 (ar) مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PH12018500569A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
PH12017500571A1 (en) Mono-or di-substituted indole derivatives as dengue viral replication inhibitors
PH12019502577A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12018502077A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12017501272A1 (en) Indole derivatives as dengue viral replication inhibitors
PH12018502015A1 (en) Substituted indole derivatives as dengue viral replication inhibitors
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12018500576A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
PH12018502026A1 (en) Substituted indole compound derivatives as dengue viral replication inhibitors
PH12018502016A1 (en) Substituted indole derivatives as dengue viral replication inhibitors
PH12017500503A1 (en) Mono- or di-substituted indoles as dengue viral replication inhibitors
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502559A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MY185672A (en) Mono-or di-substituted indole derivatives as dengue viral replication inhibitors
MY197383A (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors